Piper Sandler: 'We View Inozyme Pharma Inc. as a Diamond in the Rough'; PT Lowered
Tweet Send to a Friend
Piper Sandler analyst Allison M. Bratzel lowered the price target on Inozyme Pharma Inc. (NASDAQ: INZY) to $23.00 (from $30.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
